TRAUMAA3B1C1: Feasibility Study of Balloon Kyphoplasty in Traumatic Vertebral Fractures Needing Surgical Fixation

Sponsor
Assistance Publique - Hôpitaux de Paris (Other)
Overall Status
Terminated
CT.gov ID
NCT00749229
Collaborator
Ministry of Health, France (Other)
17
1
1
39
0.4

Study Details

Study Description

Brief Summary

Some unstable traumatic vertebral fractures (types A3.2, A3.3, B1 et C1 according to MAGERL classification) may undergo unpredictable secondary displacement. Such fractures require a two session surgery with a first operation carried out immediately to achieve posterior fixation and a second surgery which is performed some days later to stabilize the anterior spine and restore stress resistance.

Goal of the present study is to show that percutaneous Balloon Kyphoplasty is able to restore anterior spine strength and replace second session surgery.

Condition or Disease Intervention/Treatment Phase
  • Device: balloon kyphoplasty
Phase 4

Detailed Description

Patients with traumatic vertebral fractures type A3.2, A3.3, B1 and C1 of the MAGERL classification will be enrolled in this open study. They will be operated on in emergency to perform spinal canal decompression, fracture reduction and posterior fixation using fixation plates with pedicular screws combined with bone graft.

During the same surgery or some days later on, percutaneous Balloon kyphoplasty of the fractured vertebral body (ies) using polymethylmetacrylate cement injection through a posterior transpedicular approach will be carried out in replacement of anterior spine surgery to restore vertebral body strength.Patients will be followed up for one year.

Expected advantages of this management compared the conventional two session surgery include the following:

  • decreased morbidity due to suppression of the anterior surgery

  • improve final spine alignment and vertebral Kyphotic angle avoiding the loss in kyphotic angle which often occurs between the posterior and anterior surgery with the conventional two session surgery.

Study Design

Study Type:
Interventional
Actual Enrollment :
17 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Prospective Cohort Study on the Feasibility and Reliability of 'Open' Balloon Kyphoplasty in Types A3.2, A3.3, B1 and C1 MAGERL Classification Vertebral Fractures(STIC 4)
Study Start Date :
Dec 1, 2007
Actual Primary Completion Date :
Mar 1, 2011
Actual Study Completion Date :
Mar 1, 2011

Arms and Interventions

Arm Intervention/Treatment
Other: 1

Balloon kyphoplasty

Device: balloon kyphoplasty
During the same surgery or some days later on, percutaneous Balloon kyphoplasty of the fractured vertebral body (ies) using polymethylmetacrylate cement injection through a posterior transpedicular approach will be carried out in replacement of anterior spine surgery to restore vertebral body strength

Outcome Measures

Primary Outcome Measures

  1. Loss of less than 10 degrees in spine kyphosis angle at one year follow-up after surgery compared to postoperative measurements [1 year]

Secondary Outcome Measures

  1. Pain evaluation using a visual analogic scale [J-20 to J-7 - J6 - J45 - J90 - J180 - J360]

  2. EIFEL questionnaire for back pain evaluation [J-20 to J-7 - J6 - J45 - J90 - J180 - J360]

  3. Quality of life evaluation (SF 12). [J-20 to J-7 - J6 - J45 - J90 - J180 - J360]

  4. Analgesics intake according to the WHO classification (Classes 1, 2 and 3). [J-20 to J-7 - J6 - J45 - J90 - J180 - J360]

  5. Regional spine Kyphosis angle and global thoracic and lumbar Kyphosis angle. [J-20 to J-7 - J6 - J45 - J90 - J180 - J360]

  6. Changes in anterior, mid and posterior vertebral heights of the treated vertebral body [J-20 to J-7 - J6 - J45 - J90 - J180 - J360]

  7. Changes in height of the intervertebral disc spaces adjacent to the treated vertebra. [J-20 to J-7 - J6 - J45 - J90 - J180 - J360]

  8. Number of new vertebral fractures occurring during the one year follow-up period. [J-20 to J-7 - J6 - J45 - J90 - J180 - J360]

  9. Cost evaluation in a sample of 10% of patients randomly selected including the following costs : o Intervention cost.o Medical treatment costs o Consultation costs. o Hospitalization cost o Complication costs [J-20 to J-7 - J6 - J45 - J90 - J180 - J360]

  10. Follow-up of anterior, median and posterior height of the treated vertebral body, obtained by making an average of all measurements, on 3 cuts tomodensitometry (TDM) on the sagittal level : lateral right, median and lateral left [preoperative, at J6 and at J360]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Preliminary clinical examination (the anaesthesist must have provided his approval for the surgical procedure)

  • Patient must have signed the consent form

  • Male or female patient aged 18 or over

  • One or two traumatic vertebral fractures located between T11 and L5 and type A3.2, A3.3, B1 or C1 in the MAGERL classification, and with a regional kyphotic angle > 15° and treated by osteosynthesis through a posterior surgical approach with or without spinal decompression

  • Fracture with or without neurological difficulties

  • Non tumoral origin: Confirmed by biopsy at the same time of the Balloon Kyphoplasty procedure.

Exclusion Criteria:
  • Non- traumatic, malignant or osteoporotic vertebral fractures

  • History of surgical or percutaneous spine treatment except simple discectomy at a single or multiple vertebral levels with no residual pain.

  • Known allergy to a contrast media or to one of the cement components used for kyphoplasty.

  • More than two recent vertebral fractures

  • Current infection

  • Impossibility to perform the percutaneous approach of the vertebra to treat.

  • Reduction by more than 50% of the anteroposterior width of the bony spinal canal due to the vertebral fracture to treat.

  • Vertebral fracture with loss of 90%or more of the vertebral body height

  • Patient presenting a non correctable spontaneous or therapeutic coagulation disorder.

  • Evolutive cardiac disease nonreactive to medical treatment

  • Non compliant patient: Impossibility to participate to the study and to be followed up for 1 year.

  • Pregnant or breast feeding women

  • Patient not affiliated to social security

Contacts and Locations

Locations

Site City State Country Postal Code
1 Service de Radiologie, Hôpital Lariboisière Paris France 75010

Sponsors and Collaborators

  • Assistance Publique - Hôpitaux de Paris
  • Ministry of Health, France

Investigators

  • Principal Investigator: Jean-Denis LAREDO, M.D.,PR., AP/HP Assistance Publique-Hôpitaux de Paris

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT00749229
Other Study ID Numbers:
  • P060109
First Posted:
Sep 9, 2008
Last Update Posted:
Jan 4, 2017
Last Verified:
Dec 1, 2014
Keywords provided by Assistance Publique - Hôpitaux de Paris
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 4, 2017